Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | CDK4 | P11802 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | MAPK7 | Q13164 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORB | Q92753 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19641085 | 0.81 | KMO (0.38) | MAPK14 | |
| SCHEMBL19641316 | 0.80 | CCR4 (0.37) | MAPK14 | |
| SCHEMBL19641120 | 0.77 | TSHR (0.46) | JAK2GAAMAOB | |
| SCHEMBL4012971 | 0.76 | KMT2A (0.45) | KMT2ARORBMAPK14 | |
| SCHEMBL2876974 | 0.76 | GAA (0.58) | CDK2CDK4JAK2JAK1TYK2 | |
| SCHEMBL27778060 | 0.76 | SIRT6 (0.38) | MEN1KMT2A | |
| SCHEMBL14015128 | 0.72 | HPGD (0.50) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19995905 | 0.71 | KCNQ3 (0.46) | MEN1KMT2A | |
| SCHEMBL19641070 | 0.69 | SRD5A2 (0.44) | NPC1RAB9A | |
| SCHEMBL30677177 | 0.69 | LMNA (0.53) | GAAMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3463343-B1 | HETEROCYCLIC INHIBITORS OF PTPN11 | UNIV TEXAS (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-01-21 | — | — | US | disclosed |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-09-05 | — | — | US | disclosed |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3463343-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | Board of Regents, University of Texas System (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210134-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
| US-11466017-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
| US-10851110-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
| US-20190270746-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | CDK2 647/4885CDK4 482/4885JAK2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.